uniQure N.V. (QURE)

USD 15.76

(-4.25%)

Market Cap (In USD)

768.19 Million

Revenue (In USD)

15.84 Million

Net Income (In USD)

-308.47 Million

Avg. Volume

2.83 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.73-17.71
PE
-
EPS
-
Beta Value
0.902
ISIN
NL0010696654
CUSIP
N90064101
CIK
1590560
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Matthew Craig Kapusta
Employee Count
-
Website
https://www.uniqure.com
Ipo Date
2014-02-05
Details
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.